Fust Matthew K 4

What Happened Matthew K. Fust, a director of Ultragenyx Pharmaceutical Inc. (RARE), was granted equity awards on May 14, 2026 totaling 21,809 shares: 7,751 restricted stock units (RSUs) and 14,058 derivative awards. Both grants are reported at $0.00 per share (typical for company awards) and were recorded as acquisition code "A" on the Form 4 filing.

Key Details

• Transaction date: May 14, 2026; Form 4 filed May 18, 2026 (filed within the standard 2 business-day window).
• Awards: 7,751 RSUs (F1) and 14,058 derivative award/option-type units (F2); total = 21,809 shares; reported price $0.00.
• Vesting: F1 – RSUs vest in full on the earlier of the company's next Annual Meeting or May 14, 2027. F2 – the derivative/option award similarly vests in full on the earlier of the next Annual Meeting or May 14, 2027.
• Shares owned after the transaction: not specified in the provided filing summary.
• Transaction code: A = Award/Grant.

Context These were compensation awards (not open-market purchases or sales). RSUs and similar derivative grants typically vest over time or upon a specified event; they do not represent immediate sales. Such grants are routine director compensation and should be interpreted as a grant of future equity rather than a direct bullish or bearish trade signal.